Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
GlobeNewswire
*Highlights*· ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progression
·..
*Highlights*· ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progression
·..
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring..
· Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and..